Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Ethics of Biobanking and the Human Investment

Published: Tuesday, September 10, 2013
Last Updated: Tuesday, September 10, 2013
Bookmark and Share
Biobanks across South Africa collect and store thousands of biospecimens such as blood, saliva, plasma, and purified DNA?

Unisa’s College of Law (CLAW) held a seminar on the ethical and legal issues around biobanking, on 26 August 2013, to look at some of the controversial issues that are raised by the practice, such as the privacy of individuals who store their biomaterial with these banks or volunteer to assist with research.

Concerns about communicating research findings, dealing with the tissues that remain, the rights of family members, and the thorny questions of payment and benefit sharing were also considered.
Professor Omphemetse Sibanda, Director: School of Law, explained that CLAW was looking to provide legal solutions to the topic, to benefit stakeholders and influence policy development. “This discussion has a national and international context and includes arenas such as stem cell and genome research.”

Blood donors are biobankers

Many people are loyal blood donors and yet, perhaps, are unaware that the South African National Blood Service (SANBS) can be considered as one of the country’s largest biobanks, storing and collecting blood on a daily basis. Organisations such as SANBS, while adhering to legislative policies, are mostly self regulating. Dr Loyiso Mpuntsha, CEO: SANBS, says that private biobanks must adhere to strict self-regulating guidelines such as considering all stakeholders, collaboration on a local and international level, and supplying quality bio specimens. She believes that biobanks are becoming a viable alternative for researchers and medical professionals. “Biobanks are attracting the attention with the government and pharmaceutical industry and funding of contractual agreements.”

International perspectives on biobanking

From an international perspective, some countries have already instituted far-reaching legislation and laws that deal with biobanking including private networks. Iceland and Sweden have introduced laws and the United Kingdom has a human tissue act. Ma’n Zawati, Academic Associate Lawyer, Centre of Genomics and Policy, McGill University Canada, dealt with the regulation of biobanks from an international perspective, pointing out that the public are voluntarily coming forward to donate their human specimens to help research, in, for instance, clinical trials. “There is an ethical imperative attached to this because people are handing over their data but they expect biobanks to do something with this. They need to see progress or they won’t continue.”

Zawati believes that it is impossible to harmonise international law but that it is possible to harmonise the tools for biobanks by providing generic documents that countries can use, citing that they were formulated using international standards.

Establishing a public biobank in South Africa

The situation in South Africa is vastly different from its international counterparts. Currently, there is no public biobank in the country as the field comprises private companies. Professor Michael Pepper, Director: Institute for Cellular and Molecular Medicine, University of Pretoria, says they have conducted research with the Department of Health to possibly establish a public bank. “The response has been overwhelmingly positive after trials to establish a public biobank. This also speaks to the fact that the private sector has spent 150 million rand to store blood, units, stem cells and other material for several years which has not been used. There is no point in storing these cells and not using them.”

Pepper revealed that there are gaps in terms of policies as well as norms and standards but noted that more and more groups involved in human tissues have begun to self regulate and have professional bodies to ensure international standards are met. “Legislation must protect individuals from harmful or unethical practices. It must be uppermost in our minds that we make provisions for all South Africans and allow the public to benefit from advances in medical science.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!